|
|
|
16.06.25 - 13:06
|
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md. and SHANGHAI, June 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a strategic partnership to develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. SIM0505 is currently in Phase 1 clinical testing in China; NextCure expects to begin clinical testing in the U.S. in the third quarter of 2025....
|
|
|
29.05.25 - 22:06
|
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together with LigaChem Biosciences, Inc. (LigaChemBio) announced that a trial in progress poster from the Phase 1 study evaluating LNCB74, a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago....
|
|
|
04.04.25 - 13:03
|
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET....
|
|
|
|
|
|
|
|
|
|
|
26.11.24 - 13:03
|
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET....
|
|
|
19.11.24 - 14:09
|
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15th, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle bone disease in a well-established model of disease....
|
|
|
|
|
|
|
05.11.24 - 22:09
|
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed in partnership with LigaChem Biosciences (LCB) (KOSDAQ: 141080), and biomarker data from the NC410 combination study with pembrolizumab in patients with immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC). The data will be presented during poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting....
|
|
|
04.10.24 - 15:09
|
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions....
|
|
|
16.09.24 - 14:09
|
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. The trial, which is evaluating the combination in ovarian cancer and immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC), demonstrated clinical activity in these hard-to-treat cancers. The data were presented by clinical trial investigators Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center (ovarian) and Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive...
|
|
|
|
|
|
|
|
|
30.05.24 - 22:06
|
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
